Prof. Mojisola Adeyeye, agency’s Director-General, NAFDAC

The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the production of Chloroquine for clinical trials in tackling the deadly Coronavirus.

Prof. Mojisola Adeyeye, agency’s Director-General, who spoke in Lagos on Friday, stated that NAFDAC was not approving Chloroquine for the treatment of COVID-19 but for clinical trials to find treatment for the virus.

According to Channels TV, she said in the case of Chloroquine, it had been demonstrated in the literature and with clinical research which is still ongoing, that Chloroquine is superior to the Placebo.

Read Also: NAFDAC to Control Illicit Drugs, Outlines Measures

“NAFDAC is not approving Chloroquine as a product that can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.

“Therefore the medicine is being approved just for the clinical trials,” Adeyeye said.

She, therefore, called on experts and researchers that were interested in doing a clinical trial on Chloroquine to approach approved outlets, adding that a drug company had been given an approval to produce chloroquine in batches.

“Right now, we have asked one company to make a batch of Chloroquine for the purpose of clinical trial,” Adeyeye added.

Let us know

Receive Alerts on: Whatsapp: +2348022417409 facebook: @SafetyRecordNG Twitter: @SafetyRecordNG, Share your story with us: SMS: +2348022417409, Whatsapp: +2348022417409, Email: